Inici › Sobrepès › Arizona › Phoenix
Assaigs clínics de Sobrepès a Phoenix, AZ
15 estudis de Sobrepès busquen participants en centres de Phoenix i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
ReclutantFase 3
- Absolute Clinical Research, Phoenix
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
ReclutantFase 3
- RIO Clinical Trials - Phoenix, Phoenix
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
ReclutantFase 3
- Research Site, Phoenix
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
ReclutantFase 3
- Synexus Clinical Research US, Inc., Phoenix
- Medical Advancement Centers of Arizona, Phoenix
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
ReclutantFase 3
- Elite Clinical Studies, LLC, Phoenix
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
ReclutantFase 3
- AURORA-1 Clinical Site, Phoenix
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
ReclutantFase 3
- AURORA-2 Clinical Site, Phoenix
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
ReclutantFase 2
- Helios Clinical Research - Phoenix, Phoenix
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
ReclutantFase 3Voluntaris sans benvinguts
- ACCOMPLISH-2 Research Site, Phoenix
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
ReclutantFase 2
- Synexus Clinical Research US, Inc., Phoenix
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
ReclutantFase 4
- Medical Dermatology Specialists, Phoenix
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
ReclutantFase 3
- Kailera Clinical Site, Phoenix
Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity
ReclutantEstudi observacional
- Exponent Phoenix, Phoenix
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
ReclutantFase 3
- ACCOMPLISH-1 Research Site, Phoenix
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
ReclutantFase 3
- The University of Arizona College of Medicine- Phoenix, Phoenix
Assaigs de Sobrepès en altres ciutats
- San Antonio, TX34 estudis
- Houston, TX33 estudis
- Chicago, IL28 estudis
- Orlando, FL27 estudis
- Las Vegas, NV23 estudis
- Miami, FL23 estudis
- Atlanta, GA20 estudis
- Dallas, TX20 estudis
- New York City, NY19 estudis
- Jacksonville, FL19 estudis
- Washington, DC19 estudis
- Austin, TX18 estudis
Altres estudis a Phoenix
- Càncer de mama25 estudis
- Càncer colorrectal25 estudis
- Obesitat22 estudis
- Càncer de pulmó de cèl·lules no petites20 estudis
- Càncer metastàtic20 estudis
- Insuficiència cardíaca18 estudis
- Càncer de pròstata17 estudis
- Càncer (tots els tipus)17 estudis
- Mieloma múltiple16 estudis
- Càncer de pàncrees16 estudis
- Malaltia cardiovascular16 estudis
- Malaltia d'Alzheimer15 estudis
De ClinicalTrials.gov, dades recuperades el 4 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.